VIVUS Reports Third Quarter 2009 Highlights and Financi...(September 30 December 31 ...)

Date:11/3/2009

September 30, December 31, 2009 2008* ---- ---- (unaudited) Current assets: Cash and cash equivalents $127,819 $66,121 Available-for-sale securities 99,096 121,789 Accounts receivable, net 2,347 4,157 Inventories, net 2,760 3,041 Prepaid expenses and other assets 3,634 3,744 ----- ----- Total current assets 235,656 198,852 Property and equipment, net 6,104 6,726 Restricted cash 700 700 Available-for-sale securities - 1,344 Total assets $242,460 $207,622 ======== ======== Current liabilities: Accounts payable $7,208 $17,205 Deferred revenue 462 31,858 Accrued and other liabilities 14,840 14,909 ------ ------ Total current liabilities 22,510 63,972 Notes payable-net of current portion 20,104 11,177 Deferred revenue 914 1,260 --- ----- Total liabilities 43,528 76,409
'/>"/>

SOURCE VIVUS, Inc. Copyright©2009 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3 4 5 6 7 8
Related biology technology :

1. VIVUS Reports First Quarter 2009 Financial Results and Highlights
2. Data on VIVUS Qnexa To Be Presented During Two Podium Presentations at ADA Annual Meeting
3. VIVUS to Present at the Needham and Company Life Sciences Conference
4. VIVUS to Present at the Canaccord Adams 29th Annual Global Growth Conference
5. VIVUS to Present at Four Upcoming Healthcare Conferences
6. VIVUS Announces Positive Results From Two Phase 3 Studies; Obese Patients on Qnexa Achieve Average Weight Loss up to 14.7% and Significant Improvements in Co-Morbidities
7. EpiCept Reports Expansion of Clinical Development For Licensed Cancer Compound
8. QMed, Inc. Reports July Medicare SNP Enrollments
9. Phlo Affiliate Reports Expanded Coverage to Oregon Border
10. Healthcare Technologies Reports Loss for 2007 Second Quarter & Six Months Results
11. Dragon Pharmaceutical Reports Growth in Sales and Profits during Second Quarter of 2007